Year: 2005
Type: article
Abstract: recently, with the availability of HAART, new approaches to relapsed HIV-related NHL were tried.A prospective trial was published in 2003 on JCO.Sixteen patients with HIV-related NHL or HD were treated sequentially by salvage chemotherapy, followed by mobilization of PBSC with cyclophosphamide and conditioning with BEAM (BCNU, etoposide, Ara-C and melphalan).Tem patients received the AHSCT, with 7 complete and 2 partial remissions.Six patients maintained remission after 8 months of follow-up.(Re A, et al.J Clin Oncol 2003) A retrospective study in France in relapsed HIV-related NHL showed that, after AHSCT, 10 out of 14 patients achieved complete remission.After a median follow-up of 25months, 5/15 patients were alive.(Gabarre J, et al.Haematologica 2004) Recently, the group from City of Hope published a trial where 20 patients with high-risk features, in relapse or refractory, with AHSCT.With a median follow-up of more than 2.5 years, 17 out of 20 were alive in remission and toxicity was low.(Krishnan A, et al.Blood 2005) Recently trial listed above pointed to AHSCT as a valuable alternative to treat high-risk or relapsed HIVrelated NHL.Its results are far superior compared to salvage chemotherapy only.Nevertheless, this results must be taken with caution.This series are relatively small and non-controlled trials.A randomized and larger clinical trial is needed. Profiling viral gene expression in lymphomasDirk P. Dittmer
Author: Dirk P. Dittmer
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,600
OpenAlex ID: W2076841484